# US 2018/0021447 A1 · Lipid Nanoparticle Compositions and Methods of Making and Methods of Using the Same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0021447 A1
- Document ID: US20180021447A1
- Status: Published application
- Kind: A1
- Application number: 15/689,667
- Filed: 2017-08-29
- Published: 2018-01-25
- Earliest claimed: 2012-05-23
- Assignees: Ohio State Innovation Foundation
- Applicants: Ohio State Innovation Foundation
- Inventors: Robert J. Lee
- Web page: https://patentgrep.com/patent/US20180021447A1

## CPC

- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61K 9/127: Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K 9/1271: Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers (liposomes as conjugates {A61K47/6911})
- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 31/713: Double-stranded nucleic acids or oligonucleotides
- A61K 38/08: Peptides having 5 to 11 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/10: Peptides having 12 to 20 amino acids {(A61K38/043 - A61K38/046 take precedence)}
- A61K 38/482: {Serine endopeptidases (3.4.21)}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/543: {Lipids, e.g. triglycerides; Polyamines, e.g. spermine or spermidine}
- A61K 47/544: {Phospholipids}
- A61K 47/549: {Sugars, nucleosides, nucleotides or nucleic acids}
- A61K 47/59: obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K 47/62: the modifying agent being a protein, peptide or polyamino acid
- A61K 47/643: {Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]}
- A61K 47/6907: {the form being a microemulsion, nanoemulsion or micelle}
- A61K 47/6911: {the form being a liposome}
- A61P 35/00: Antineoplastic agents
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/1135: {against oncogenes or tumor suppressor genes}
- C12N 15/1137: {against enzymes (viral enzymes C12N15/1131; receptors C12N15/1138)}
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C12N 2310/11: Antisense
- C12N 2310/14: interfering nucleic acids [NA]
- C12Y 304/21064: Peptidase K (3.4.21.64)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

Lipid nanoparticle formulations, methods of making, and methods of using same are disclosed.

## Claims

### Claim 1

A lipid nanoparticle comprising a combination of tertiary and quaternary amine-based cationic lipids, except not, wherein said combination consists of the tertiary amine-cationic lipid present at about 40.0 molar percent; wherein the tertiary amine-cationic lipid comprises N-[1-(2, 3-dioleyloyx) propyl]-N—N—N-dimethyl ammonium chloride (DODMA), and the concentration of the quaternary amine-cationic lipid present at about 5.0 molar percent.

### Claim 2 (depends on 1)

The lipid nanoparticle of claim 1, wherein the tertiary amine-cationic lipids are chosen from DODAP, DODMA, DC-CHOL, N,N-dimethylhexadecylamine, or combinations thereof.

### Claim 3 (depends on 1)

The lipid nanoparticle of claim 1, wherein the quaternary amine-cationic lipids are selected from DOTAP, DOTMA, DDAB, or combinations thereof.

### Claim 4 (depends on 1)

The lipid nanoparticle of claim 1, wherein the concentration of the tertiary amine-cationic lipids is below 60.0 molar percent of the total lipid content.

### Claim 5 (depends on 1)

The lipid nanoparticle of claim 1, wherein the concentration of quaternary amine-cationic lipids is below 20.0 molar percent of the total lipid content.

### Claim 6 (depends on 1)

The lipid nanoparticle of claim 1, wherein the nanoparticle encapsulates molecules selected from nucleic acids, proteins, polysaccharides, lipids, radioactive substances, therapeutic agents, prodrugs, nutritional supplements, biomarkers, or combinations thereof.

### Claim 7 (depends on 6)

The lipid nanoparticle of claim 6, wherein the encapsulated molecules comprise a nucleic acid selected from plasmid DNAs, antisense oligonucleotides, miRs, anti-miRs, shRNAs, siRNAs, or combinations thereof.

### Claim 8 (depends on 1)

The lipid nanoparticle of claim 1, further comprising a cationic polymer.

### Claim 9 (depends on 8)

The lipid nanoparticle of claim 8, wherein the cationic polymer is selected from the group consisting of: spermine, dispermine, trispermine, tetraspermine, oligospermine, thermine, spermidine, dispermidine, trispermidine, oligospermidine, putrescine, polylysine, polyarginine, a polyethylenimine of branched or linear type, and polyallylamine.

### Claim 10 (depends on 1)

The lipid nanoparticle of claim 1, further comprising a fusogenic peptide.

### Claim 11 (depends on 6)

The lipid nanoparticle of claim 6, wherein the encapsulation rate of therapeutic agents or nucleotides is 20% or higher.

### Claim 12 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle has a diameter under 300 nm.

### Claim 13 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle comprises the lipids DODMA and DOTMA in a molar ratio selected from 45:0, 5:40, 15:30, 22.5:22.5, 30:15, or 40:5.

### Claim 14 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle comprises the lipids DMHDA and DOTAP in a molar ratio selected from 90:10, 70:30, 50:50, 30:70, or 10:90.

### Claim 15

A lipid nanoparticle having a diameter of less than 300 nm and comprising a peptide.

### Claim 16 (depends on 15)

The lipid nanoparticle of claim 15, wherein the peptide is selected from gramicidin A, B, C, D, or S; JTS-1; proteinase K (PrK); trichorovin-Xlla; rabies virus glycoprotein; interleukin-1 β; HIV-Tat; herpes simplex virus VP22 protein; and combinations thereof.

### Claim 17 (depends on 15)

The lipid nanoparticle of claim 15, wherein the peptide comprises an antibiotic.

### Claim 18 (depends on 17)

The lipid nanoparticle of claim 17, wherein the antibiotic is selected from gramicidin A, B, C, D, or S.

### Claim 19 (depends on 15)

The lipid nanoparticle of claim 15, wherein the peptide consists essentially of a lipidated JTS-1 fusogenic peptide.

### Claim 20 (depends on 19)

The lipid nanoparticle of claim 19, wherein the lapidated JTS-1 fusogenic peptide is present at about 0 to about 30 molar percent of the total formulation.

### Claim 21 (depends on 15)

The lipid nanoparticle of claim 15, further comprising proteinase K.

### Claim 22 (depends on 15)

The lipid nanoparticle of claim 15, wherein the proteinase K is present at about 0 to about 30 molar percent of the total formulation.

### Claim 23 (depends on 15)

The lipid nanoparticle of claim 15, wherein the lipid nanoparticle encapsulates molecules selected from nucleic acids, proteins, polysaccharides, lipids, radioactive substances, therapeutic agents, prodrugs, nutritional supplements, biomarkers, or combinations thereof.

### Claim 24 (depends on 23)

The lipid nanoparticle of claim 23, wherein the encapsulated molecules comprise a nucleic acid selected from plasmid DNAs, antisense oligonucleotides, miRs, anti-miRs, shRNAs, siRNAs, or combinations thereof.

### Claim 25

A lipid nanoparticle comprising a DNase- or RNase-degrading agent.

### Claim 26 (depends on 25)

The lipid nanoparticle of claim 25, wherein the DNase- or RNase-degrading agent consists essentially of proteinase K.

### Claim 27 (depends on 25)

The lipid nanoparticle of claim 25, wherein the nanoparticle encapsulates molecules selected from nucleic acids, proteins, polysaccharides, lipids, radioactive substances, therapeutic agents, prodrugs, nutritional supplements, biomarkers, or combinations thereof.

### Claim 28 (depends on 27)

The lipid nanoparticle of claim 27, wherein the encapsulated molecules comprise an oligonucleotide selected from pDNAs, antisense oligonucleotides, miRs, anti-miRs, shRNAs, siRNAs, or combinations thereof.

### Claim 29 (depends on 25)

The lipid nanoparticle of claim 25, wherein the lipid nanoparticle has a diameter under 300 nm.

### Claim 30

A lipid nanoparticle having a diameter of less than 300 nm and comprising a combination of two or more of:
a mixture of tertiary and quaternary amine-cationic head groups;
an antibiotic; or
a DNase or RNase-degrading agent.

### Claim 31 (depends on 30)

The lipid nanoparticle of claim 30, wherein the RNase or RNase-degrading agent consists essentially of proteinase K.

### Claim 32 (depends on 30)

The lipid nanoparticle of claim 30, wherein the antibiotic comprises gramicidin A, B, C, D, or S.

### Claim 33 (depends on 1)

A lipid nanoparticle of claim 1, further comprising a polyethyleneglycol-lipid conjugate.

### Claim 34 (depends on 33)

The lipid nanoparticle of claim 33, wherein the polyethyleneglycol-lipid conjugate selected from polysorbate 80, TPGS, mPEG-DSPE, PEG-DMG, DPPE-PEG or mPEG-DMPE.

### Claim 35 (depends on 33)

The lipid nanoparticle of claim 33, wherein the polyethyleneglycol-lipid is present at a concentration less than about 10.0 molar percent.

### Claim 36 (depends on 33)

A lipid nanoparticle of claim 33, further comprising N,N-dimethylhexadecylamine.

### Claim 37 (depends on 36)

The lipid nanoparticle of claim 36, wherein the N,N-dimethylhexadecylamine is present at a concentration of less than about 60.0 molar percent of the formulation.

### Claim 38 (depends on 36)

A lipid nanoparticle of claim 36, further comprising a ligand capable of binding to a target cell or a target molecule.

### Claim 39 (depends on 38)

The lipid nanoparticle of claim 38, wherein the ligand is an antibody or an antibody fragment.

### Claim 40 (depends on 38)

The lipid nanoparticle of claim 38, wherein the ligand is selected from cRGD, galatose-containing moieties, transferrin, folate, low density lipoprotein, or epidermal growth factors.

### Claim 41 (depends on 1)

A pharmaceutical composition comprising a lipid nanoparticle of claim 1, and a pharmaceutically acceptable excipient.

### Claim 42 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is administered perorally, intravenously, intraperitoneally, subcutaneously, or transdermally.

### Claim 43 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is prepared as an orally administered tablet.

### Claim 44 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is prepared as a sterile solution.

### Claim 45 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is prepared as a sterile suspension.

### Claim 46 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is prepared as a lyophilized powder.

### Claim 47 (depends on 41)

The pharmaceutical composition of claim 41, wherein the pharmaceutical composition is prepared as a suppository.

### Claim 48 (depends on 41)

A method of diagnosing or treating a cancer or infectious disease, the method comprising administering an effective amount of a pharmaceutical composition of claim 41 to a patient in need thereof.

### Claim 49 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle encapsulates at least one molecule selected from nucleic acids, chemotherapeutic agents, and combinations thereof.

### Claim 50 (depends on 49)

The lipid nanoparticle of claim 49, wherein the encapsulated molecule comprises a nucleic acid selected from plasmid DNAs, antisense oligonucleotides, miRs, anti-miRs, shRNAs, siRNAs, and combinations thereof.

### Claim 51 (depends on 49)

The lipid nanoparticle of claim 49, wherein the encapsulated molecule comprises a therapeutic agent selected from: antineoplastic agents, anti-infective agents, local anesthetics, anti-allergics, antianemics, angiogenesis, inhibitors, beta-adrenergic blockers, calcium channel antagonists, anti-hypertensive agents, anti-depressants, anti-convulsants, anti-bacterial, anti-fungal, anti-viral, anti-rheumatics, anthelminithics, antiparasitic agents, corticosteroids, hormones, hormone antagonists, immunomodulators, neurotransmitter antagonists, anti-diabetic agents, anti-epileptics, anti-hemmorhagics, anti-hypertonics, antiglaucoma agents, immunomodulatory cytokines, sedatives, chemokines, vitamins, toxins, narcotics, imaging agents, and combinations thereof.

### Claim 52 (depends on 49)

The lipid nanoparticle of claim 49, wherein the encapsulated molecule comprises a nucleic acid therapeutic agent.

### Claim 53 (depends on 52)

The lipid nanoparticle of claim 52, wherein the nucleic acid therapeutic agent is selected from: pDNA, siRNA, miRNA, anti-miRNA, ASO, and combinations thereof.

### Claim 54 (depends on 52)

The lipid nanoparticle of claim 52, wherein the nucleic acid therapeutic agent is stabilized by modifications to substituent NA base units and/or by modifying the ribose 2′ position or substituting phosphodiester linkers.

### Claim 55 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle has a diameter under about 300 nm.

### Claim 56 (depends on 1)

The lipid nanoparticle of claim 1, wherein the lipid nanoparticle has a diameter under about 200 nm.

### Claim 57 (depends on 1)

The lipid nanoparticle of claim 1, wherein the polymer is bound to an external surface of the lipid via direct connection or via a linker.

### Claim 58 (depends on 16)

The lipid nanoparticle of claim 16, wherein the lipid nanoparticle has an encapsulation efficiency of the molecule of at least about 40%.

### Claim 59 (depends on 1)

The lipid nanoparticle of claim 1, further including a polyethylene glycol-conjugated lipid.

### Claim 60 (depends on 59)

The lipid nanoparticle of claim 59, wherein the polyethylene glycol-conjugated lipid comprises one or more of: polysorbate 80, TPGS, DPPE-PEG, mPEG-DMPE, and mPEG-DSPE.

### Claim 61 (depends on 27)

The lipid nanoparticle of claim 27, wherein the polyethylene glycol-conjugated lipid is present at a concentration less than about 15.0 molar percent.

### Claim 62 (depends on 1)

The lipid nanoparticle of claim 1, further comprising a ligand capable of binding to a target cell or a target molecule.

### Claim 63 (depends on 62)

The lipid nanoparticle of claim 62, wherein the ligand is an antibody or an antibody fragment.

### Claim 64 (depends on 62)

The lipid nanoparticle of claim 62, wherein the ligand is selected from cRGD, galatose-containing moieties, transferrin, folate, low density lipoprotein, or epidermal growth factors.

### Claim 65 (depends on 1)

A pharmaceutical composition comprising the lipid nanoparticle of claim 1, and a pharmaceutically acceptable excipient.

### Claim 66 (depends on 65)

The pharmaceutical composition of claim 65, wherein the pharmaceutical composition is administered perorally, intravenously, intraperitoneally, subcutaneously, or transdermally.

### Claim 67 (depends on 65)

The pharmaceutical composition of claim 65, wherein the pharmaceutical composition is prepared as an orally administered tablet, an inhalant, or a suppository.

### Claim 68 (depends on 65)

The pharmaceutical composition of claim 65, wherein the pharmaceutical composition is prepared as a sterile solution, a sterile suspension, or a lyophilized powder.

### Claim 69

A lipid nanoparticle comprising, an anti-miR-221 and SPLN-G20, wherein SPLN-G20 comprises: DMHDA, DOTAP, GRAM, DOPE and TPGS at a molar ratio of 40:5:20:30:5.

### Claim 70 (depends on 69)

The lipid nanoparticle of claim 69, wherein the anti-miR-221 has the sequence: 5′-gsasaacccagcagacaaugusasgscsu-Chol-3′, SEQ ID NO. 1.

### Claim 71 (depends on 70)

The lipid nanoparticle of claim 70, wherein the sequence includes 2′-O-Methyl-modified oligonucleotides (lower case letters) and phosphorothioate linkages (s subscript) to increase nuclease stability of the oligonucleotides.

### Claim 72

A composition comprising anti-miR-221 combined a lipid nanoparticle.

### Claim 73 (depends on 72)

The composition of claim 72, wherein the lipid nanoparticle comprises SPLN-G20v1 and SPLN-G20v2, wherein SPLN-G20 version 1 (SPLN-G20v1) comprises DMHDA, DOTAP, GRAM, DOPE and TPGS at a molar ratio of 40:5:20:30:5, and wherein SPLN-G20 (SPLN-G20v2) comprises DODAP, DOTAP, GRAM, Soy PC (SPC) and TPGS at a molar ratio of 40:5:20:30:5.

### Claim 74 (depends on 73)

The composition of claim 73, wherein the lipid nanoparticle comprises SPLN-G20v1 and SPLN-G20v2 at an N:P of 15:1.

### Claim 75 (depends on 69)

A method of treating a subject having, or suspected of having, breast cancer, comprising administering an effective amount of the lipid nanoparticle of claim 69.

### Claim 76 (depends on 69)

A method of providing anti-oncogenic effect in a subject suffered from breast cancer, in which miR-221 expression level is higher in cancer cells of case subject relative to a control subject, comprising administering to the subject an effective amount of a composition of claim 69.

### Claim 77 (depends on 76)

The method of claim 76, wherein the lipid nanoparticle down-regulates miR-221 expression.

### Claim 78 (depends on 76)

The method of claim 76, wherein the breast cancer comprises triple negative breast cancer.

### Claim 79 (depends on 78)

The method of claim 78, wherein the subject is a human.

### Claim 80

A composition comprising anti-miR-155 combined with a lipid nanoparticle.

### Claim 81 (depends on 80)

The composition of claim 80, wherein the lipid nanoparticle comprises Lac-GLN, wherein Lac-GLN comprises a lipophilic asialoglycoprotein receptor (ASGR) targeting ligand composed of lactobionic acid (LA), bearing a galactose moiety, and linked to a phospholipid.

### Claim 82 (depends on 80)

The composition of claim 80, further including gramicidin A incorporated into the lipid nanoparticle.

### Claim 83 (depends on 82)

The composition of claim 82, comprising DODAP, Lac-DOPE, DOPE, DMG-PEG and gramicidin A at a molar ratio of 50:10:28:2:10.

### Claim 84 (depends on 80)

The composition of claim 80, wherein the anti-miR-155 has the sequence: 5′-A*C*CCCUAUCACGAUUAGCAUU*A*A-3′, SEQ ID NO. 6.

### Claim 85 (depends on 84)

The composition of claim 84, wherein the sequence contains phosphorothioate linkages (*) and 2′-O-Methyl.

### Claim 86 (depends on 80)

A method of treating a subject having, or suspected of having liver cancer, comprising administering an effective amount of the lipid nanoparticle of claim 80.

### Claim 87 (depends on 80)

A method of providing anti-oncogenic effect in a subject suffered from liver cancer, in which miR-155 expression level is higher in cancer cells of case subject relative to a control subject, comprising administering to the subject an effective amount of the lipid nanoparticle of claim 80.

### Claim 88 (depends on 87)

The method of claim 87, wherein the lipid nanoparticle down-regulates C/EBPβ and FOXP3 genes.

### Claim 89 (depends on 86)

The method of claim 86, wherein the subject is a human.
